Integrated Multi-Omic Analyses Support Distinguishing Secretory Carcinoma of the Breast from Basal-Like Triple-Negative Breast Cancer

Proteomics. Clinical Applications
Min-Sun JinHan Suk Ryu

Abstract

Secretory carcinoma (SC) of the breast is defined as an indolent tumor but is still categorized into a basal-like triple-negative breast cancer (BL-TNBC) subgroup that generally shows aggressive behavior according to the current classification. Despite the unique clinical behavior of SC, molecular characteristics that reflect biological behaviors of SC remain largely unknown. A combinatorial approach of whole-exome sequencing and mass spectrometry-based in-depth quantitative proteomics to determine the entire molecular landscape of SC using three SC formalin-fixed paraffin-embedded (FFPE) tissues is employed. Exome sequencing and proteomic analysis of SC identified 419 unique somatic mutations and 721 differentially expressed proteins as compared with triple-negative breast cancer (TNBC), respectively. Several pathways related to cancer metabolism were significantly upregulated in the SC group. Comparative analyses with multiple datasets revealed that SC shares genomic mutations and biological pathways more closely related to hormone receptor-positive breast cancer than BL-TNBC. These multi-omic analyses provide evidence that SC harbors substantially different molecular genomic and proteomic landscapes compared with BL-TNBC. Th...Continue Reading

References

Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·T SørlieA L Børresen-Dale
Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Nov 18, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Marick LaéAnne Vincent-Salomon
Jan 10, 2009·Nature Protocols·Da Wei HuangRichard A Lempicki
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel S ParkerPhilip S Bernard
Apr 21, 2009·Nature Methods·Jacek R WiśniewskiMatthias Mann
Jun 30, 2009·Journal of Clinical Pathology·M B K LambrosJ S Reis-Filho
Apr 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Elizabeth H HammondAntonio C Wolff
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Jun 29, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Apr 15, 2014·Nature Biotechnology·Juan A VizcaínoHenning Hermjakob
Jul 22, 2014·Nature·Bing ZhangUNKNOWN NCI CPTAC
Apr 4, 2015·Analytical Chemistry·Jacek R Wiśniewski, Fabienne Z Gaugaz
Jan 5, 2016·Nature Communications·Stefka TyanovaTamar Geiger
Apr 5, 2016·Journal of Surgical Oncology·John Doromal JacobVicki Suzanne Klimberg
Jun 28, 2016·Nature Methods·Stefka TyanovaJürgen Cox
May 27, 2017·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Gregor KringsYunn-Yi Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.